KHDRBS1 as a novel prognostic signaling biomarker influencing hepatocellular carcinoma cell proliferation, migration, immune microenvironment, and drug sensitivity

Sep 21, 2026

Integrating public multi-omics and multi-cohort data with clinical samples and molecular biology validation, the study characterizes KHDRBS1 as a prognostic signaling biomarker in hepatocellular carcinoma (HCC). Single-cell sequencing data are used to separate malignant cells into KHDRBS1-positive and KHDRBS1-negative subsets, revealing distinct expression patterns and functional roles. Results demonstrate that KHDRBS1 positivity tracks with tumor progression and promotes oncogenic phenotypes linked to cell proliferation, migration, immune microenvironment changes, and drug sensitivity.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages16

Reading Time40 min

AccessFree to download

Introduction

Background and rationale

Methods

Multi-omics integration and validation

Single-cell subset analysis

Results

KHDRBS1 tumor-promoting role

Clinical significance of KHDRBS1-positive cells

Conclusion

TYPE Original Research PUBLISHED 10 April 2024 DOI 10.3389/fimmu.2024.1393801 OPEN ACCESS EDITED BY Wenhong Deng, Renmin Hospital of Wuhan University, China REVIEWED BY Jing Zhang, University of South Dakota, United States Chao Li, LMU Munich University Hospital, Germany *CORRESPONDENCE Dongyan Shen [shendongyan@xmu.edu.cn](shendongyan@xmu.edu.cn) †These authors have contributed equally to this work RECEIVED 29 February 2024 ACCEPTED 27 March 2024 PUBLISHED 10 April 2024 CITATION Fan R, Liu F, Gong Q, Liu D, Tang S and Shen D (2024) KHDRBS1 as a novel prognostic signaling biomarker inﬂuencing hepatocellular carcinoma cell proliferation, migration, immune microenvironment, and drug sensitivity. Front. Immunol. 15:1393801 . doi: 10.3389/fimmu.2024.1393801 COPYRIGHT © 2024 Fan, Liu, Gong, Liu, Tang and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. KHDRBS1 as a novel prognostic signaling biomarker inﬂuencing hepatocellular carcinoma cell proliferation, migration, immune microenvironment, and drug sensitivity Rui Fan 1†, Fahui Liu 1†, Qiming Gong 2,3†, Donghua Liu 1, Shihang Tang 1 and Dongyan Shen 1* 1Xiamen Cell Therapy Research Center, The First Afﬁliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, 2 Department of Nephrology, Afﬁliated Hospital of Youjiang Medical University for Nationalities, Baise, China, 3 Baise Key Laboratory for Metabolic Diseases (Youjiang Medical University for Nationalities), Education Department of Guangxi Zhuang Autonomous Region, Baise, China Background: Human tumors pose signiﬁcant challenges, with targeted therapy against speciﬁc molecular targets or signaling pathways being a mainstay alongside surgical resection. Previous studies have implicated KHDRBS1 in the oncogenesis of certain human tumors such as colorectal and prostate cancers, underscoring its potential as a therapeutic target. However, the comprehensive expression pattern of KHDRBS1 in hepatocellular carcinoma (HCC) warrants further exploration. Methods: Integrating and analyzing multi-omics, multi-cohort data from public databases, coupled with clinical samples and molecular biology validation, we elucidate the oncogenic role of KHDRBS1 in HCC progression. Additionally, leveraging HCC single-cell sequencing data, we segregate malignant cells into KHDRBS1-positive and negative subsets, uncovering signiﬁcant differences in their expression proﬁles and functional roles. Results: Our study identiﬁes KHDRBS1 as a tumor-promoting factor in HCC, with its positivity correlating with tumor progression. Furthermore, we highlight the clinical signiﬁcance of KHDRBS1-positive malignant cells, aiming to further propel its clinical utility. Conclusion: KHDRBS1 plays a key role in HCC development. This study provides crucial insights for further investigation into KHDRBS1 as a therapeutic target in HCC. KEYWORDS HCC, KHDRBS1, immune, migration, multi-omics, biomarker Frontiers in Immunology 01 [frontiersin.org](frontiersin.org) 1 Introduction Hepatocellular carcinoma (HCC), a highly lethal malignancy worldwide, has long been a focal point in the medical community (1) . Treatment modalities for HCC have evolved from traditional surgical resection, radiotherapy, and chemotherapy to more reﬁned approaches such as molecular targeted therapy and immunotherapy. Molecular targeted agents like sorafenib have become standard therapy for advanced HCC patients, while immunotherapy, particularly immune checkpoint inhibitors like nivolumab, has shown promis

FAQs

What is the main objective of this study regarding KHDRBS1 in HCC?

To determine whether KHDRBS1 functions as a novel prognostic signaling biomarker influencing HCC cell proliferation, migration, immune microenvironment, and drug sensitivity.

How did the study analyze KHDRBS1-related mechanisms?

It integrated and analyzed multi-omics, multi-cohort data from public databases and validated findings using clinical samples and molecular biology, then leveraged HCC single-cell sequencing to compare KHDRBS1-positive versus negative malignant cells.

What do the results indicate about KHDRBS1 in tumor progression?

KHDRBS1 is identified as a tumor-promoting factor, and KHDRBS1 positivity correlates with tumor progression, with clinical significance highlighted for KHDRBS1-positive malignant cells.

Sep 21, 2026

Uploaded by Ava Thompson